Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia
- PMID: 24876745
- PMCID: PMC4033462
- DOI: 10.3748/wjg.v20.i20.6244
Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia
Abstract
Risk calculators are widely used in many clinical fields, and integrate several important risk factors through the conversion of a risk function into a single measure of risk. Several studies have been carried out to create risk calculators for the prediction of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Most of them were hospital-based, with limited sample sizes and insufficient external validation. These study groups collaborated to establish the REACH-B risk score, which incorporated five clinical variables to predict HCC risk. This risk score was then validated in international clinical cohorts. Evidence suggests that quantitative serum HBsAg level provides additional predictability of HCC, especially in patients with low levels of hepatitis B virus DNA. This novel marker was incorporated into a risk calculator and was internally validated. This tool will hopefully be externally validated in the near future. Risk calculators can be used to support clinical practice, and to establish preventive measures; several "off-label" extension usages have also been implemented. Albeit beneficial, several precautions and discussions should be noted in using the risk calculators. The future development of risk calculators for CHB patients can be extended by applying them to additional CHB-related outcomes, and by incorporating emerging risk parameters.
Keywords: Chronic hepatitis B; Hepatitis B virus; Hepatocellular carcinoma; Risk calculator.
Figures



Similar articles
-
Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients.World J Gastroenterol. 2016 Oct 7;22(37):8314-8321. doi: 10.3748/wjg.v22.i37.8314. World J Gastroenterol. 2016. PMID: 27729738 Free PMC article. Review.
-
Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.Clin Gastroenterol Hepatol. 2016 Mar;14(3):461-468.e2. doi: 10.1016/j.cgh.2015.10.033. Epub 2015 Nov 18. Clin Gastroenterol Hepatol. 2016. PMID: 26598229
-
The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.Gut. 2016 Sep;65(9):1514-21. doi: 10.1136/gutjnl-2015-310686. Epub 2015 Dec 7. Gut. 2016. PMID: 26642861
-
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.Aliment Pharmacol Ther. 2020 Jun;51(11):1169-1179. doi: 10.1111/apt.15725. Epub 2020 Apr 14. Aliment Pharmacol Ther. 2020. PMID: 32291781
-
What can we learn from hepatitis B virus clinical cohorts?Liver Int. 2015 Jan;35 Suppl 1:91-9. doi: 10.1111/liv.12716. Liver Int. 2015. PMID: 25529093 Review.
Cited by
-
Hepatocellular carcinoma risk scores: ready to use in 2015?Hepat Oncol. 2015 Jan;2(1):1-4. doi: 10.2217/hep.14.32. Epub 2015 Jan 12. Hepat Oncol. 2015. PMID: 30190979 Free PMC article. No abstract available.
-
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatol Int. 2016 Jan;10(1):1-98. doi: 10.1007/s12072-015-9675-4. Epub 2015 Nov 13. Hepatol Int. 2016. PMID: 26563120 Free PMC article.
-
Chronic hepatitis B in remote, tropical Australia; successes and challenges.PLoS One. 2020 Sep 3;15(9):e0238719. doi: 10.1371/journal.pone.0238719. eCollection 2020. PLoS One. 2020. PMID: 32881958 Free PMC article.
-
Personalized management of hepatocellular carcinoma based on molecular information: future prospects.Clin Liver Dis (Hoboken). 2015 Jun 1;5(6):132-135. doi: 10.1002/cld.483. Clin Liver Dis (Hoboken). 2015. PMID: 26213619 Free PMC article. No abstract available.
-
Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia.Clin Epidemiol. 2017 Dec 21;10:41-49. doi: 10.2147/CLEP.S146275. eCollection 2018. Clin Epidemiol. 2017. PMID: 29339926 Free PMC article.
References
-
- World Health Organization. Fact Sheet: Hepatitis B. 2008. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/
-
- Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107. - PubMed
-
- Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067–1077. - PubMed
-
- Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S294–S308. - PubMed
-
- Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical